Last updated: December 22, 2025
Summary
PROMETRIUM, the brand name for Megestrol Acetate, is a progestin derivative primarily used to treat appetite stimulation in cachexia, endometrial cancer, and hormone-responsive breast cancer. Its market landscape is shaped by regulatory approvals, clinical indications, patent status, competition, and emerging biosimilar options. This analysis delineates the current market dynamics, financial trajectory, and competitive positioning of PROMETRIUM, emphasizing supply-demand drivers, revenue forecasts, and strategic considerations for industry stakeholders.
What is PROMETRIUM?
| Parameter |
Details |
| Generic Name |
Megestrol Acetate |
| Brand Name |
PROMETRIUM (Pfizer) |
| Therapeutic Class |
Progestin; appetite stimulant; hormonal therapy |
| Primary Uses |
Appetite stimulation in cachexia, endometrial & breast cancer |
| Approval Date |
FDA: 1979; EMA: 1979 |
| Formulations |
Oral tablets (20 mg, 40 mg), injectable (less common) |
Market Overview and Drivers
Global Market Size and Growth (2023-2028)
| Region |
Market Size (USD Billion, 2022) |
CAGR (2023-2028) |
Key Drivers |
| North America |
0.8 |
4.5% |
High prevalence of cancer, aging population, reimbursement policies |
| Europe |
0.4 |
3.8% |
Similar demographic trends, regulatory approvals |
| Asia-Pacific |
0.3 |
6.2% |
Growing cancer burden, expanding healthcare infrastructure |
| Latin America & MEA |
0.2 |
4.1% |
Rising awareness, increasing cancer cases |
Total Market (2022): Approx. USD 1.7 billion
Projected (2028): Approx. USD 2.4 billion
Source: Global Data and MarketsandMarkets reports[1],[2]
Key Market Drivers
- Cancer Prevalence: Approximately 19 million new cancer cases globally annually; cachexia affects about 50% of advanced cancer patients[3].
- Aging Population: Seniors (>60 years) increasingly require palliative care, driving demand.
- Regulatory Approvals & Off-label Use: Supportive approvals for appetite stimulation expand usage.
- Reimbursement Policies: Favorable insurance coverage bolsters market accessibility.
Market Restraints
- Availability of Alternatives: Other appetite stimulants like corticosteroids and cannabinoids.
- Patent Expiry & Generics: Multiplicity of generic megestrol acetate products impacting pricing & revenues.
- Side Effect Profile: Risks such as thromboembolism limit broad use.
Competitive Landscape
| Key Players |
Market Share (2023) |
Notable Products |
Strategic Moves |
| Pfizer (PROMETRIUM) |
~45% |
PROMETRIUM (brand) |
Focus on niche indications, biosimilar entry |
| Mylan / Viatris |
~20% |
Generic Megestrol Acetate |
Cost leadership, expanding access |
| Teva, Sun Pharma, Others |
Remainder |
Various generics |
Price competition, regional dominance |
Patent & Regulatory Status
- Patent Timeline: The original patent expired in the early 2000s, leading to numerous generics.
- FDA & EMA Approvals: Approvals cover common indications; off-label use is prevalent.
- Biosimilars & Generics: Increased market penetration has reduced average selling prices (ASPs).
Financial Trajectory: Revenue Projections & Profitability
Historical Financial Performance
| Year |
Estimated Revenue (USD million) |
Comments |
| 2018 |
120 |
Brand dominance, limited generic options |
| 2019 |
110 |
Entry of generics, price erosion |
| 2020 |
95 |
COVID-19 impact, supply disruptions |
| 2021 |
100 |
Market stabilization |
| 2022 |
105 |
Resumption of demand |
Forecast for 2023-2028
| Year |
Estimated Revenue (USD million) |
CAGR (Projected) |
Key Assumptions |
| 2023 |
105 |
2.8% |
Steady demand, biosimilar competition stabilizes |
| 2024 |
108 |
2.8% |
Increased use in oncology supportive care |
| 2025 |
112 |
3.0% |
Expansion into emerging markets |
| 2026 |
115 |
2.7% |
Market saturation of current indications |
| 2027 |
118 |
2.6% |
Introduction of new formulations or indications |
| 2028 |
122 |
3.3% |
Growing elderly care segments |
Note: Revenue estimates account for generic price erosion, regional growth, and new indications.
Profitability Considerations
- Pricing Pressure: Generic saturation reduces ASPs.
- Cost Structure: Diversification into off-label uses and formulations entails variable costs.
- Market Share Stability: Niche positioning in specific indications preserves margins despite competition.
Emerging Trends & Strategic Insights
Biosimilars & Generics
| Impact |
Description |
| Price Erosion |
Generics capture >80% of volume, lowering ASPs |
| Market Entry Barriers |
Regulatory requirements for biosimilars vary regionally |
| Opportunities |
Cost-effective options for healthcare systems, expansion into emerging markets |
Regulatory & Reimbursement Policies
- Stringent approvals for off-label indications may hinder rapid market expansion.
- Reimbursement policies favor established products with proven safety and efficacy data.
Innovative Formulations & Uses
- Development of extended-release formulations.
- Exploration of combination therapies in oncology supportive care.
Pipeline & Future Indications
| Potential Indications |
Development Stage |
Notes |
| Chemotherapy-induced nausea |
Early-stage |
Enhancement through combinational approaches |
| Cachexia in chronic illness |
Regulatory approvals pending |
Growing demand in cachectic populations outside oncology |
Regulatory & Policy Environment
| Region |
Key Policies & Considerations |
| FDA (US) |
Supports generic drug diffusion, off-label use regulation |
| EMA (Europe) |
Similar to FDA, with emphasis on biosimilar approvals |
| China & India |
Expanding approvals, evolving patent laws, price controls |
| Global Trends |
Emphasis on affordable access, increased biosimilar approvals |
Comparative Analysis: PROMETRIUM Versus Alternatives
| Parameter |
PROMETRIUM (Megestrol Acetate) |
Corticosteroids (e.g., Dexamethasone) |
Cannabinoids (e.g., Dronabinol) |
| Main Use |
Appetite stimulation; hormone therapy |
Anti-inflammatory, antiemetic |
Appetite stimulation, anti-nausea |
| Efficacy |
Well-established in cachexia |
Similarly effective; broader use |
Emerging evidence; variable |
| Side Effects |
Thromboembolism, fluid retention |
Hyperglycemia, mood changes |
Psychoactive effects, addiction potential |
| Cost |
Moderate (generic options available) |
Generally low-income settings |
Higher, depending on regulation & access |
Key Challenges & Opportunities
| Challenges |
Opportunities |
| Patent expirations and generic competition |
Cost reduction, wider access through biosimilars and generics |
| Off-label use regulation complexities |
Expansion into broader indications, personalized medicine |
| Side effect profile management |
Development of safer formulations |
| Market consolidation and price competition |
Strategic partnerships, regional market penetration |
Key Takeaways
- The global market for PROMETRIUM is expected to grow modestly (~3% CAGR) through 2028, driven by aging demographics, rising cancer prevalence, and expanding healthcare infrastructure.
- Generic competition and biosimilars significantly erode ASPs, necessitating strategic repositioning for brand dominance.
- Sales are concentrated in North America and Europe, with emerging markets offering substantial growth potential.
- The primary revenue streams are from oncology supportive care and hormonal therapy indications; off-label usage remains a critical driver.
- Regulatory environments are becoming more permissive towards biosimilars, presenting both challenges (price erosion) and opportunities (cost-effective access).
- Future growth may depend on formulation innovations, new indication approvals, and increased access in low-resource settings.
FAQs
1. What are the primary medical indications for PROMETRIUM?
PROMETRIUM is principally used for appetite stimulation in cachectic cancer patients, as well as hormonal therapy in endometrial and hormone-responsive breast cancers.
2. How has patent expiration impacted PROMETRIUM's market?
Patent expiration in the early 2000s led to widespread generic manufacturing, significantly reducing prices but increasing market competition, which has constrained Pfizer’s revenue share for PROMETRIUM.
3. What are the key drivers for future growth in PROMETRIUM’s market?
Growth will be driven by increased cancer patient populations, expanding use in underserved geographies, development of new formulations, and potential new indications such as cachexia in chronic illnesses.
4. How do biosimilars influence the market landscape?
Biosimilars and generics drive down prices and increase accessibility, but they also intensify price competition, requiring brand companies to innovate or focus on niche indications.
5. Are there ongoing developments to improve PROMETRIUM’s safety profile?
Research into safer formulations and combination therapies aims to mitigate side effects like thromboembolism, thereby broadening patient eligibility.
References
- MarketsandMarkets. Global Oncology Supportive Care Market Forecast, 2022.
- Global Data. Pharmaceutical Market Trends, 2022.
- National Cancer Institute. Cancer Cachexia Statistics, 2022.
- U.S. Food and Drug Administration (FDA). Drug Approvals and Labeling, 1979-2022.
- European Medicines Agency (EMA). Market Authorization Reports, 2022.
Disclaimer: This analysis reflects market conditions and available data as of 2023 and should be supplemented with ongoing market intelligence for strategic decision-making.
